Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

B. K.M. Reddy, V. Lokesh*, M. S. Vidyasagar, K. Shenoy, K. G. Babu, A. Shenoy, T. Naveen, Bindhu Joseph, R. Bonanthaya, Nanjundappa, P. P. Bapsy, Loknatha, Jayarama Shetty, Krishna Prasad, C. R. Tanvir Pasha

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

100 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science